Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Kaempferol suppresses proliferation and induces apoptosis and DNA damage in human gallbladder cancer cells through the CDK4/CDK6/cyclin D1 pathway.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Liu ZQ;Liu ZQ; Yao GL; Zhai JM; Hu DW; Fan YG
- Source:
European review for medical and pharmacological sciences [Eur Rev Med Pharmacol Sci] 2021 Feb; Vol. 25 (3), pp. 1311-1321.
- Publication Type:
Journal Article
- Language:
English
- Additional Information
- Source:
Publisher: Verduci Country of Publication: Italy NLM ID: 9717360 Publication Model: Print Cited Medium: Internet ISSN: 2284-0729 (Electronic) Linking ISSN: 11283602 NLM ISO Abbreviation: Eur Rev Med Pharmacol Sci Subsets: MEDLINE
- Publication Information:
Original Publication: Rome : Verduci, [1997-
- Subject Terms:
- Abstract:
Objective: Kaempferol has been reported to play an anti-tumor role in various human cancers, while its role in gallbladder cancer (GBC) is unclear.
Materials and Methods: We found that kaempferol significantly inhibited the growth, invasion and migration, meanwhile induced apoptosis through cells arrested at G0/G1 phase of GBC cell lines, including GBC-SD and SGC996 cells in vitro.
Results: Kaempferol promoted the release of cytochrome C from the mitochondria to cytoplasm, the activation of c-caspase-3 and c-caspase-9 and increased the expression levels of pro-apoptotic factor Bax, meanwhile decreased the expression levels of anti-apoptotic factor Bcl-2. In addition, the expression levels of CDK4, CDK6 and cyclin D1, which are members of the CDK4/CDK6/cyclin D1 signaling pathway, were also decreased by kaempferol. Moreover, kaempferol could efficiently prevent tumor progression of GBC in the xenograft in vivo.
Conclusions: Our results demonstrated that kaempferol suppressed GBC progression through activation of the CDK4/CDK6/cyclin D1 signaling pathway, suggesting that it might be a potential anti-tumor agent for clinical treatment of GBC.
- Accession Number:
0 (Antineoplastic Agents)
0 (CCND1 protein, human)
0 (Kaempferols)
136601-57-5 (Cyclin D1)
731P2LE49E (kaempferol)
EC 2.7.11.22 (CDK4 protein, human)
EC 2.7.11.22 (CDK6 protein, human)
EC 2.7.11.22 (Cyclin-Dependent Kinase 4)
EC 2.7.11.22 (Cyclin-Dependent Kinase 6)
- Publication Date:
Date Created: 20210225 Date Completed: 20210913 Latest Revision: 20210913
- Publication Date:
20231215
- Accession Number:
10.26355/eurrev_202102_24836
- Accession Number:
33629301
No Comments.